Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GU

PSMA PET/CT for prostate cancer patients after focal therapy: a single center retrospective analysis

Mahbod Jafarvand, Andrea Farolfi, Matthias Benz, LOIC DJAILEB, Riccardo Mei, Johannes Czernin, Leonard Marks and Jeremie Calais
Journal of Nuclear Medicine June 2023, 64 (supplement 1) P1241;
Mahbod Jafarvand
1University of California, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Farolfi
2Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Benz
1University of California, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LOIC DJAILEB
3UCLA Ahmanson Biological Imaging Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Riccardo Mei
4Universita' degli Studi di Bologna - Policlinico S. Orsola-Malpighi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johannes Czernin
5Ahmanson Translational Theranostics Division, Pharmacology, University of California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonard Marks
6David Geffen School of Medicine at UCLA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremie Calais
1University of California, Los Angeles
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Article Figures & Data

Figures

  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 64, Issue supplement 1
June 1, 2023
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PSMA PET/CT for prostate cancer patients after focal therapy: a single center retrospective analysis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
PSMA PET/CT for prostate cancer patients after focal therapy: a single center retrospective analysis
Mahbod Jafarvand, Andrea Farolfi, Matthias Benz, LOIC DJAILEB, Riccardo Mei, Johannes Czernin, Leonard Marks, Jeremie Calais
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P1241;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
PSMA PET/CT for prostate cancer patients after focal therapy: a single center retrospective analysis
Mahbod Jafarvand, Andrea Farolfi, Matthias Benz, LOIC DJAILEB, Riccardo Mei, Johannes Czernin, Leonard Marks, Jeremie Calais
Journal of Nuclear Medicine Jun 2023, 64 (supplement 1) P1241;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Real-World Single-Center Response, Survival and Safety Analysis of Pluvicto in Metastatic Castration-Resistant Prostate Cancer
  • Comparison of Post-Therapy 4 and 24-hour 177Lu-PSMA SPECT/CT and Pre-Therapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castrate-Resistant Prostate Cancer
  • Applying Staging PSMA PET/CT in De Novo Metastatic Hormonal Sensitive Prostate Cancer (mHSPC): A Preliminary Single-Center Retrospective Review of Clinical Outcomes
Show more Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GU

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire